XiaoMao Li

Dr. XiaoMao Li

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2020 in Aging
Verified
Journal Article
Open access
PCPeigen Chen
Peigen Chen
YYYuebo Yang
Yuebo Yang
YZYu Zhang
Yu Zhang
SJSenwei Jiang
Senwei Jiang
XLXiaoMao Li
XiaoMao Li
JWJing Wan
Jing Wan
Endometrial cancer (EC) is one of the most common gynecologic malignancies. To identify potential prognostic biomarkers for EC, we analyzed the relationship between the EC tumor microenvironment and gene expression profiles. Using the ESTIMATE R tool, we found that immune and stromal scores correlated with clinical data and the prognosis of EC patients. Based on the immune and stromal scores, 387 intersection differentially expressed genes were identified. Eight immune-related genes were then identified using two machine learning algorithms. Functional enrichment analysis revealed that these genes were mainly associated with T cell activation and response. Kaplan-Meier survival analysis showed that expression of TMEM150B, CACNA2D2, TRPM5, NOL4, CTSW, and SIGLEC1 significantly correlated with overall survival times of EC patients. In addition, using the TIMER algorithm, we found that expression of TMEM150B, SIGLEC1, and CTSW correlated positively with the tumor infiltration levels of B cells, CD8+ T cells, CD4+ T cells, macrophages, and dendritic cells. These findings indicate that the composition of the tumor microenvironment affects the clinical outcomes of EC patients, and suggests that it may provide a basis for development of novel prognostic biomarkers and immunotherapies for EC patients.

31 October 2025 in BMC Public Health
Verified
Journal Article
Open access
PDF file
SQShiyuan Qi
Shiyuan Qi
QCQi Chen
Qi Chen
JLJinghong Liang
Jinghong Liang
XYXiaohui Yang
Xiaohui Yang
XLXiaoMao Li
XiaoMao Li
Cervical cancer continues to pose a significant global health burden for women, especially in low-resource settings. Although HPV vaccination and screening programs are available, public awareness remains limited. Social media platforms have become major sources of health information; however, the quality of content varies considerably. This study assesses the quality, reliability, and dissemination patterns of cervical cancer–related videos on YouTube, Bilibili, and TikTok, with a focus on how uploader characteristics influence information accuracy. On February 21, 2025, we retrieved the top 100 videos using the keyword “cervical cancer” on YouTube, and its Chinese equivalent “宫颈癌” on Bilibili and TikTok. Two independent reviewers evaluated video quality using the Global Quality Score (GQS), Video Information and Quality Index (VIQI), modified DISCERN (mDISCERN), and Patient Education Materials Assessment Tool (PEMAT). Inter-rater agreement was assessed, and statistical analysis was performed using non-parametric tests and Spearman correlation. A total of 84 YouTube videos, 82 Bilibili videos, and 91 TikTok videos were included. TikTok videos showed significantly higher user engagement than those on other platforms (p<0.001), but scored significantly lower in GQS, VIQI, mDISCERN, and PEMAT evaluations (p<0.001). Videos uploaded by professionals consistently received higher quality scores than those from non-professionals. (p<0.001) Although TikTok had higher uploader activity, its content was largely based on personal experiences, lacking scientific rigor and practical guidance. The video quality on TikTok and Bilibili is negatively correlated with their interactivity. The three platforms show distinct differences in how cervical cancer–related health information is disseminated. TikTok demonstrates superior dissemination and engagement performance, whereas YouTube provides higher content quality and credibility. These findings underscore the importance of leveraging each platform’s strengths to promote evidence-based health communication.

25 February 2020 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
JDJie Ding
Jie Ding
XZXu Zhang
Xu Zhang
CCChuangqi Chen
Chuangqi Chen
YHYuqiang Huang
Yuqiang Huang
XYXingsu Yu
Xingsu Yu
XLXiaoMao Li
XiaoMao Li
Endometrial carcinoma is a kind of epithelial malignant tumor occurring in the endometrium with high incidence (nearly 200 000 people are diagnosed every year). At present, surgery is the main strategy for the treatment of endometrial carcinoma. However, in special cases such as serous, clear cell carcinoma and postoperative recurrences, chemotherapy is still essential and indispensable. The combined chemotherapy schemes of cisplatin, paclitaxel and doxorubicin (DOX) in clinical applications are unfortunately complicated and easily cause severe side effects. In recent years, with the development of nanotechnology, the targeted delivery of multi-chemotherapeutic drugs shows great advantages in reducing side effects and improving anticancer efficacy. Here, an ultra pH-sensitive nanovesicle based on polyethylene glycol-poly(diisopropylamino)ethyl methacrylate (PEG-PDPA) was fabricated. A chemotherapeutic drug (doxorubicin) and an anti-apoptotic Bcl-2 inhibitor (navitoclax) were co-encapsulated in the hydrophilic cavity and hydrophobic membrane of the vesicle, respectively. After accumulating in the tumor tissue via the enhanced permeability and retention (EPR) effect, the nanovesicles could be efficiently diffused in tumor cells by endocytosis and then rapidly release drugs in response to the lysosomal acidic environment, leading to an enhanced tumor-killing effect based on the combination therapy between DOX and the Bcl-2 inhibitor. The drug co-delivery system and microenvironment-triggered drug release may provide an efficient strategy for endometrial carcinoma therapy.

12 June 2019 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
WLWenjuan Liao
Wenjuan Liao
XTXinran Tang
Xinran Tang
XLXiaoMao Li
XiaoMao Li
TLTian Li
Tian Li

21 January 2020 in Disease Markers
Verified
Journal Article
Open access
PDF file
JWJia Wang
Jia Wang
XLXiaoMao Li
XiaoMao Li
HWHaotian Wu
Haotian Wu
YZYu Zhang
Yu Zhang
FWFei Wang
Fei Wang
Background. The safety and effectiveness of robotic surgery are evaluated by comparing perioperative outcomes with laparoscopy and laparotomy in endometrial cancer. Method. PubMed, MEDLINE, Embase, Cochrane, and other databases were searched for eligible studies up to April 2019. Studies that compared robotic surgery with laparoscopy or laparotomy in surgical staging of endometrial cancer were included. The pooled odds ratio and weighted mean difference were calculated using a random-effects or a fixed-effects model to summarize the results. Results. Twenty-seven articles were ultimately included, with one randomized controlled trial and 26 observational studies. A total of 6568 patients were included. Meta-analysis showed that robotic surgery had less estimated blood loss (P<0.001), blood transfusion (P=0.04), intraoperative complications (P=0.001), and conversion to open surgery (P=0.001), and a shorter hospital stay (P=0.001), but had a longer operation time (P=0.04) in surgical staging of endometrial cancer compared with laparoscopy. There were no significant differences in postoperative complications, the total number of lymph nodes harvested, the number of pelvic lymph nodes harvested, and the number of para-aortic lymph nodes harvested between techniques. Robotic surgery had a longer operation time (P=0.008), less estimated blood loss (P<0.001), blood transfusion (P<0.001), and postoperative complications (P<0.001), and a shorter hospital stay (P<0.001) compared with laparotomy. There were no significant differences in other variables between techniques. Conclusion. Robotic surgery is a safer surgical approach than laparoscopy and laparotomy in surgical staging of endometrial cancer, with less estimated blood loss, blood transfusion, and conversion, and the same number of lymph nodes harvested.

21 July 2023 in Journal of Infection and Public Health
Verified
Journal Article
Open access
JHJiang Huiyun
Jiang Huiyun
DJDing Jie
Ding Jie
WHWang Huan
Wang Huan
YYYuebo Yang
Yuebo Yang
XLXiaoMao Li
XiaoMao Li
To assess the prevalence and characteristics of human papillomavirus (HPV) genotypes and its associated cervical lesions in Guangzhou, China, which may be useful for adjusting area-specific cervical cancer prevention and control strategies. A total of 58630 women were enrolled. Cervical specimens were collected for HPV DNA testing and/or cervical cytology. Patients with visible cervical lesions or abnormal screening results underwent further cervical biopsies. The overall HPV positive rate was 14.07%. The top five genotypes in Guangzhou were HPV 52 (3.06%), HPV 16 (2.28%), HPV 58 (1.80%), HPV 51 (1.32%), and HPV 39 (1.15%). The prevalence of overall HPV and vaccine-targeted HPV genotypes showed a significantly decreasing trend from 2016 to 2019 (P < 0.05). While, the infection rate of HPV 35 increased significantly during this time (P = 0.015). The age-specific prevalence of any HPV genotypes showed a bimodal curve, which peaked firstly among the < 20 y age group, and then peaked secondly among the > 59 y age group. Among HPV-positive women, the proportions of HSIL and cervical cancer increased significantly with age (P < 0.05). Among > 59 y age group, 9.35% HPV-positive cases were diagnosed as cervical cancer. HPV 16/18 was the most common cause of cervical cancer. While, the percentage of non-HPV 16/18 infection among cervical cancer patients increased over time, from 15.21% in 2015 to 26.32% in 2019 (P = 0.010). Besides that, the prevalence of non-HPV 16/18 genotypes among cervical cancer patients significantly increased with age, which peaked at the > 59 y age group (P = 0.014). Although the prevalence of any HPV and vaccine-targeted HPV genotypes decreased significantly with time, it is still important to follow the HPV genotypes and their associated cancer risk after the large-scale popularization of HPV vaccine. And age should be taken into consideration in screening strategies and risk-based management of cervical cancer in Guangzhou.